{"count":32,"next":"https://lda.gov/api/v1/filings/?filing_specific_lobbying_issues=H.R.+1262&filing_year=2026&ordering=-filing_year&page=2","previous":null,"results":[{"url":"https://lda.gov/api/v1/filings/9fb65ecc-d100-4763-bfdc-17860017431d/","filing_uuid":"9fb65ecc-d100-4763-bfdc-17860017431d","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/9fb65ecc-d100-4763-bfdc-17860017431d/print/","filing_document_content_type":"text/html","income":null,"expenses":"50973.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"Steve Issenman","dt_posted":"2026-04-10T12:57:08-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"10 W. Lafayette Street","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Trenton","registrant_state":"NJ","registrant_zip":"08608","registrant":{"id":75251,"url":"https://lda.gov/api/v1/registrants/75251/","house_registrant_id":36035,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","description":"government affairs for biopharmaceutical and medical device trade association","address_1":"10 W. Lafayette Street","address_2":null,"address_3":null,"address_4":null,"city":"Trenton","state":"NJ","state_display":"New Jersey","zip":"08608","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STEVE ISSENMAN","contact_telephone":"+1 732-729-9619","dt_updated":"2026-07-15T15:26:57.674024-04:00"},"client":{"id":167699,"url":"https://lda.gov/api/v1/clients/167699/","client_id":12,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-12-08"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information, H.R. 4132 and S. 2027. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting \"cap and smooth\" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to \"Most Favored Nation\" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program. Supporting the RESULTS Act, HR 5269 and S.2761. Opposing CMS GUARD and GLOBE pricing model proposals. Opposing HR 3375 and S 1587, \"Most Favored Nation\" legislation. Supporting the PBM FAIR Act, H.R. 68937 and S. 3549.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":45619,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"ISSENMAN","suffix":null,"suffix_display":null},"covered_position":"Cong. Page (87-88), Congressional Aide (1990's)","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/48fe7c81-f956-47fb-9d8e-aebe387bef78/","filing_uuid":"48fe7c81-f956-47fb-9d8e-aebe387bef78","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/48fe7c81-f956-47fb-9d8e-aebe387bef78/print/","filing_document_content_type":"text/html","income":null,"expenses":"120000.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"John Aguilar","dt_posted":"2026-04-16T10:58:03-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"20 F St NW","registrant_address_2":"Suite 600","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":401106576,"url":"https://lda.gov/api/v1/registrants/401106576/","house_registrant_id":45596,"name":"ALLIANCE FOR REGENERATIVE MEDICINE","description":null,"address_1":"20 F St NW","address_2":"Suite 600","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JOHN AGUILAR","contact_telephone":"+1 202-344-4149","dt_updated":"2026-07-22T11:41:31.159263-04:00"},"client":{"id":51347,"url":"https://lda.gov/api/v1/clients/51347/","client_id":51347,"name":"ALLIANCE FOR REGENERATIVE MEDICINE","general_description":"Advocacy organization supporting advances in regenerative medicine.","client_government_entity":null,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2022-04-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products. Value-based payment legislation and related CMS regulations. FDA appropriations and staffing. Biologics regulation. Prescription Drug User Fee Act (PDUFA). Medicaid. Medicare. Accelerating Kids Access to Care Act (S. 752 / H.R.1509). Mikaela Naylon Give Kids a Chance Act (S. 932 / H.R. 1262). Rare Pediatric Disease Priority Review Vouchers. Bipartisan Health Care Act (S. 891). MVP Act (S.1637). NIH appropriations. HHS oversight. HHS staffing and OPM issues. Medical research. Pharmaceutical tariffs. Biotechnology manufacturing. Newborn screening. FDA oversight.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152687,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"AGUILAR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/b61e96b2-3412-4795-9479-cc82759463cf/","filing_uuid":"b61e96b2-3412-4795-9479-cc82759463cf","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/b61e96b2-3412-4795-9479-cc82759463cf/print/","filing_document_content_type":"text/html","income":null,"expenses":"130000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Heather Strawn","dt_posted":"2026-04-16T15:47:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1455 Pennsylvania Ave NW","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":400426042,"url":"https://lda.gov/api/v1/registrants/400426042/","house_registrant_id":null,"name":"LUNDBECK LLC","description":"Specialty and Central Nervous System Bio-pharmaceutical manufacturing","address_1":"1455 Pennsylvania Ave NW","address_2":"Suite 400","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"HEATHER STRAWN","contact_telephone":"+1 202-412-1563","dt_updated":"2026-07-29T13:14:27.156557-04:00"},"client":{"id":190625,"url":"https://lda.gov/api/v1/clients/190625/","client_id":12,"name":"LUNDBECK LLC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2009-03-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues pertaining to the 340B Drug Discount Program - H.R. 5256, the 340B ACCESS Act; H.R.4581 & S. 2372, 340B PATIENTS Act of 2025 Issues pertaining to Pharmacy Benefit Managers - H.R.4317, PBM Reform Act of 2025; H.R.6703, Lower Health Care Premiums for All Americans Act Step therapy reform - H.R. 5509 & S. 2903, Safe Step Act Neuroscience Drug Program - FY 2026 and FY2027 AgFDA Appropriations BRAIN Initiative - FY 2026 and FY2027 Labor-HHS Appropriations Reauthorization of the Pediatric Priority Review Voucher program at the FDA Issues related to DTC advertising regulations Pediatric rare diseases - H.R. 1262 & S. 932, Give Kids a Chance Act of 2025 Headache disorders treatment and research - H.R. 5536, HEADACHE Act of 2025 Research and services for epilepsy - H.R. 1189 & S. 494, National Plan for Epilepsy Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66159,"prefix":null,"prefix_display":null,"first_name":"HEATHER","nickname":null,"middle_name":null,"last_name":"STRAWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143282,"prefix":null,"prefix_display":null,"first_name":"HAYLEY","nickname":null,"middle_name":null,"last_name":"ALEXANDER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152053,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"POSS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153397,"prefix":null,"prefix_display":null,"first_name":"DARBIN","nickname":null,"middle_name":null,"last_name":"WOFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues pertaining to the 340B Drug Discount Program - H.R. 5256, 340B ACCESS Act; H.R.4581 & S. 2372, 340B PATIENTS Act of 2025 Issues pertaining to the implementation of the Inflation Reduction Act of 2022 - H.R. 6166, Lowering Drug Costs for American Families Act Issues pertaining to Pharmacy Benefit Managers - S.3345, PBM Price Transparency and Accountability Act; H.R.4317, PBM Reform Act of 2025 Issues pertaining to CMS Coverage of APS in LTC Issues pertaining to Medicares Six Protected Classes policy Medicare Part D Smoothing Benefit - FY 2026 and FY2027 Labor-HHS Appropriations Orphan drug exclusion in the Inflation Reduction Act - H.R. 946 & S. 1862, ORPHAN Cures Act Small molecule discrepancy in the Inflation Reduction Act - H.R. 1492 & S. 832, The EPIC Act Issues pertaining to the Most Favored Nation drug price setting policy - H.R. 7837, Most Favored Patient Act of 2026 Issues pertaining to migraine screening for women in Medicare - FY 2026 and FY2027 Labor-HHS Appropriations","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":66159,"prefix":null,"prefix_display":null,"first_name":"HEATHER","nickname":null,"middle_name":null,"last_name":"STRAWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":143282,"prefix":null,"prefix_display":null,"first_name":"HAYLEY","nickname":null,"middle_name":null,"last_name":"ALEXANDER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152053,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"POSS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153397,"prefix":null,"prefix_display":null,"first_name":"DARBIN","nickname":null,"middle_name":null,"last_name":"WOFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Tariffs on pharmaceutical products","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":143282,"prefix":null,"prefix_display":null,"first_name":"HAYLEY","nickname":null,"middle_name":null,"last_name":"ALEXANDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66159,"prefix":null,"prefix_display":null,"first_name":"HEATHER","nickname":null,"middle_name":null,"last_name":"STRAWN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152053,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"POSS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":153397,"prefix":null,"prefix_display":null,"first_name":"DARBIN","nickname":null,"middle_name":null,"last_name":"WOFFORD","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/7804bcfc-0e92-42a7-84ac-105910126753/","filing_uuid":"7804bcfc-0e92-42a7-84ac-105910126753","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/7804bcfc-0e92-42a7-84ac-105910126753/print/","filing_document_content_type":"text/html","income":"10000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Eugenia Edwards Pierson","dt_posted":"2026-04-17T14:54:14-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"601 Massachusetts Ave. NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20001","registrant":{"id":4301,"url":"https://lda.gov/api/v1/registrants/4301/","house_registrant_id":31381,"name":"ARNOLD & PORTER KAYE SCHOLER LLP","description":"Law firm","address_1":"601 Massachusetts Ave. NW","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20001","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"NICHOLAS TOWNSEND","contact_telephone":"+1 202-942-5249","dt_updated":"2026-07-30T11:53:37.108571-04:00"},"client":{"id":61903,"url":"https://lda.gov/api/v1/clients/61903/","client_id":61903,"name":"NEURELIS, INC.","general_description":"Biopharmaceutical company specializing in treatments for neurological conditions.","client_government_entity":null,"client_self_select":false,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2024-10-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Policy issues related to federal regulation of the healthcare industry and rare diseases, including the Give Kids a Chance Act (119th, H.R. 1262 / S. 932) and the Retaining Access and Restoring Exclusivity (RARE) Act (118th, H.R. 7383 / S. 1214).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":102193,"prefix":null,"prefix_display":null,"first_name":"BOBBY","nickname":null,"middle_name":null,"last_name":"MCMILLIN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140808,"prefix":null,"prefix_display":null,"first_name":"SONJA","nickname":null,"middle_name":null,"last_name":"NESBIT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/2ccaaa08-8c15-423c-bbe5-4d5458fc50d4/","filing_uuid":"2ccaaa08-8c15-423c-bbe5-4d5458fc50d4","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/2ccaaa08-8c15-423c-bbe5-4d5458fc50d4/print/","filing_document_content_type":"text/html","income":null,"expenses":"70000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Annie Kennedy","dt_posted":"2026-04-20T10:06:27-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1012 14th NW, Suite 500","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":401106105,"url":"https://lda.gov/api/v1/registrants/401106105/","house_registrant_id":null,"name":"RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)","description":"Nonprofit, nonpartisan organization dedicated to empowering rare disease patient community","address_1":"1012 14th NW, Suite 500","address_2":null,"address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"ANNIE KENNEDY","contact_telephone":"+1 202-697-7273","dt_updated":"2026-10-16T13:50:48.525272-04:00"},"client":{"id":210900,"url":"https://lda.gov/api/v1/clients/210900/","client_id":12,"name":"RARE FOUNDATION (FORMERLY KNOWN AS EVERYLIFE FOUNDATION FOR RARE DISEASES)","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-04-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 822, H.R. 1532 - Scientific EXPERT Act of 2025; S. 932, H.R. 1262 - Give Kids a Chance Act of 2025; S. 752, H.R. 1509 - Accelerating Kids Access to Care Act; H.R. 4709 - Newborn Screening Saves Lives Reauthorization Act of 2025; FY 2027 Appropriations","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":101949,"prefix":null,"prefix_display":null,"first_name":"JAMIE","nickname":null,"middle_name":null,"last_name":"SULLIVAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":101951,"prefix":null,"prefix_display":null,"first_name":"DYLAN","nickname":null,"middle_name":null,"last_name":"SIMON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/88a6ffbd-8400-46ef-af8c-de6159486b34/","filing_uuid":"88a6ffbd-8400-46ef-af8c-de6159486b34","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/88a6ffbd-8400-46ef-af8c-de6159486b34/print/","filing_document_content_type":"text/html","income":null,"expenses":"3930000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Courtney Piron","dt_posted":"2026-04-20T11:37:51-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"801 PENNSYLVANIA AVENUE, NW","registrant_address_2":"Suite 700","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":9204,"url":"https://lda.gov/api/v1/registrants/9204/","house_registrant_id":33589,"name":"NOVARTIS","description":"Federal Government Relations/Legislative Affairs","address_1":"801 Pennsylvania Avenue, NW","address_2":"Suite 700","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"COURTNEY PIRON","contact_telephone":"+1 202-662-4364","dt_updated":"2026-07-22T10:55:30.763850-04:00"},"client":{"id":113305,"url":"https://lda.gov/api/v1/clients/113305/","client_id":12,"name":"NOVARTIS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2010-12-07"},"lobbying_activities":[{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"Anti-Trust Reform","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 Funding for FDA - FY 2026 Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act 2026 FY 2026 President's Budget Request Inflation Reduction Act of 2022 (P.L. 117-169) Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 Federal Budget Funding for National Institutes of Health - FY 2026 Appropriations H.R. 1: One Big Beautiful Bill Act (P.L. 119-21) FY 2027 President's Budget H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75)","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) Restrictions on Intellectual Property Rights PTAB reform Patent fee policy issues","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152665,"prefix":null,"prefix_display":null,"first_name":"NANCY","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152572,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":"ANDREW","last_name":"SUTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Direct to Consumer Advertising 340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act HR. 5256 - 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program 340B drug discount program rebate and policy issues 340B rebate pilot program Accelerated Approval Breast Cancer Research H.R.3037, Access to Breast Cancer Diagnostic Act of 2025 S.1500, Access to Breast Cancer Diagnostic Act of 2025 Alternative Funding Programs Supply Chain Integrity and Traceability PBM Reform Modernizing and Ensuring PBM Accountability (MEPA) Act Coverage of Accelerated Approval Products Drug Benefit Design Orphan Drug Issues S. 1682/H.R.946: ORPHAN Cures Act S.932/H.R. 1262: Give Kids a Chance Act of 2025 Innovation in Pediatric Drugs Act S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Lower Costs, More Transparency Act Lower Costs, More Cures Act Medicare Part B Physician-Administered Products Patient Cost-Sharing and Smoothing Step Therapy Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications H.R. 2214: DRUG Act User fee policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues FDA regulatory approval authority policy issues Competition policy issues Clinical trial diversity policy issues Patient assistance program policy issues Drug shortages policy issues Artificial intelligence policy issues IRA price negotiation expansion policy issues Rare Pediatric Disease Priority Review Voucher program policies SUSTAIN RFI/discussion draft Most Favored Nation (MFN) policy Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Utilization management policies","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152665,"prefix":null,"prefix_display":null,"first_name":"NANCY","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152572,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":"ANDREW","last_name":"SUTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule H.R. 950: Saving Seniors Money on Prescriptions Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues S. 832/H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025 Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues H.R. 5391/S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Domestic and International Tax Policy Issues Research & Development Tax Credit Reforms Foreign Direct Investment Expensing of R&D Expenditures H.R. 2425 - Unfair Tax Prevention Act of 2025 Tax Cuts and Jobs Act, PL 115-97 H.R. 1: One Big Beautiful Bill Act (P.L. 119-21)","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Sec. 301 pharmaceutical tariffs US-UK Framework Agreement Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues International pharmaceutical pricing and reimbursement policy issues Supply chain policy issues China outbound investment policy issues US Swiss Trade Agreement US Trade Policy Sec. 232 pharmaceutical tariffs Pharmaceutical manufacturing policy and investment issues","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":61408,"prefix":null,"prefix_display":null,"first_name":"LEO","nickname":null,"middle_name":"A","last_name":"FARBER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152665,"prefix":null,"prefix_display":null,"first_name":"NANCY","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152572,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":"ANDREW","last_name":"SUTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/77e48ed2-227f-4d6b-a853-cc6bd15f2efb/","filing_uuid":"77e48ed2-227f-4d6b-a853-cc6bd15f2efb","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/77e48ed2-227f-4d6b-a853-cc6bd15f2efb/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Solveig L Monson","dt_posted":"2026-04-20T11:44:07-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1341 G Street, NW","registrant_address_2":"Suite 1100","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":284950,"url":"https://lda.gov/api/v1/registrants/284950/","house_registrant_id":36893,"name":"MEHLMAN CONSULTING, INC.","description":"Government Affairs Consulting Services","address_1":"1341 G Street, NW","address_2":"Suite 1100","address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"SOLVEIG MONSON","contact_telephone":"+1 202-585-0292","dt_updated":"2026-10-20T18:04:37.956203-04:00"},"client":{"id":175633,"url":"https://lda.gov/api/v1/clients/175633/","client_id":1006195,"name":"ASSOCIATION OF ACCESSIBLE MEDICINES","general_description":"Trade Association","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-03-10"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Issues related to generic medicines.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":27658,"prefix":null,"prefix_display":null,"first_name":"BRUCE","nickname":null,"middle_name":null,"last_name":"MEHLMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":5659,"prefix":null,"prefix_display":null,"first_name":"DEAN","nickname":null,"middle_name":null,"last_name":"ROSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":7381,"prefix":"mr","prefix_display":"MR.","first_name":"DAVID","nickname":null,"middle_name":"R","last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":11329,"prefix":null,"prefix_display":null,"first_name":"ELISE","nickname":null,"middle_name":null,"last_name":"FINLEY PICKERING","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61179,"prefix":null,"prefix_display":null,"first_name":"SAGE","nickname":null,"middle_name":null,"last_name":"EASTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62201,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"ARONSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62279,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"ROBINSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69162,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"TOLAR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70218,"prefix":null,"prefix_display":null,"first_name":"NICHOLE","nickname":null,"middle_name":null,"last_name":"DISTEFANO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71503,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"THORNELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":101897,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":"M.","last_name":"COTE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":101395,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"PERKINS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":101614,"prefix":null,"prefix_display":null,"first_name":"ROSEMARY","nickname":null,"middle_name":null,"last_name":"GUTIERREZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107920,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"MALLOVE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141084,"prefix":null,"prefix_display":null,"first_name":"CAITLIN","nickname":null,"middle_name":null,"last_name":"VAN SANT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141085,"prefix":null,"prefix_display":null,"first_name":"LISA","nickname":null,"middle_name":null,"last_name":"GOLDMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144745,"prefix":null,"prefix_display":null,"first_name":"ALYENE","nickname":null,"middle_name":null,"last_name":"MLINAR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145248,"prefix":"ms","prefix_display":"MS.","first_name":"ERICA","nickname":null,"middle_name":"JAY","last_name":"CHABOT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146767,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOLF","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147548,"prefix":null,"prefix_display":null,"first_name":"NAVEEN","nickname":null,"middle_name":null,"last_name":"PARMAR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149379,"prefix":null,"prefix_display":null,"first_name":"JON","nickname":null,"middle_name":null,"last_name":"ADAME","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151069,"prefix":"mr","prefix_display":"MR.","first_name":"JOSEPH","nickname":null,"middle_name":"EDWARD","last_name":"BROWN","suffix":"iii","suffix_display":"III"},"covered_position":null,"new":false},{"lobbyist":{"id":152223,"prefix":null,"prefix_display":null,"first_name":"EARL","nickname":null,"middle_name":"SCOTT","last_name":"FLOOD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to generic and biosimilar medications.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":27658,"prefix":null,"prefix_display":null,"first_name":"BRUCE","nickname":null,"middle_name":null,"last_name":"MEHLMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":5659,"prefix":null,"prefix_display":null,"first_name":"DEAN","nickname":null,"middle_name":null,"last_name":"ROSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":7381,"prefix":"mr","prefix_display":"MR.","first_name":"DAVID","nickname":null,"middle_name":"R","last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":11329,"prefix":null,"prefix_display":null,"first_name":"ELISE","nickname":null,"middle_name":null,"last_name":"FINLEY PICKERING","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61179,"prefix":null,"prefix_display":null,"first_name":"SAGE","nickname":null,"middle_name":null,"last_name":"EASTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62201,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"ARONSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62279,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"ROBINSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69162,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"TOLAR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70218,"prefix":null,"prefix_display":null,"first_name":"NICHOLE","nickname":null,"middle_name":null,"last_name":"DISTEFANO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71503,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"THORNELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":101897,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":"M.","last_name":"COTE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":101395,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"PERKINS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":101614,"prefix":null,"prefix_display":null,"first_name":"ROSEMARY","nickname":null,"middle_name":null,"last_name":"GUTIERREZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107920,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"MALLOVE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141084,"prefix":null,"prefix_display":null,"first_name":"CAITLIN","nickname":null,"middle_name":null,"last_name":"VAN SANT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141085,"prefix":null,"prefix_display":null,"first_name":"LISA","nickname":null,"middle_name":null,"last_name":"GOLDMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144745,"prefix":null,"prefix_display":null,"first_name":"ALYENE","nickname":null,"middle_name":null,"last_name":"MLINAR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145248,"prefix":"ms","prefix_display":"MS.","first_name":"ERICA","nickname":null,"middle_name":"JAY","last_name":"CHABOT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146767,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOLF","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147548,"prefix":null,"prefix_display":null,"first_name":"NAVEEN","nickname":null,"middle_name":null,"last_name":"PARMAR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149379,"prefix":null,"prefix_display":null,"first_name":"JON","nickname":null,"middle_name":null,"last_name":"ADAME","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151069,"prefix":"mr","prefix_display":"MR.","first_name":"JOSEPH","nickname":null,"middle_name":"EDWARD","last_name":"BROWN","suffix":"iii","suffix_display":"III"},"covered_position":null,"new":false},{"lobbyist":{"id":152223,"prefix":null,"prefix_display":null,"first_name":"EARL","nickname":null,"middle_name":"SCOTT","last_name":"FLOOD","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to pharmaceutical manufacturing supply chain. S. 1040 - Drug Competition Enhancement Act; H.R. 5526/S. 1954 -Biosimilar Red-tape Elimination Act; H.R. 3269 - ETHIC Act; S. 43 - Skinny Labels, Big Savings Act; H.R. 1843/S. 1302- Increasing Transparency in Generic Drug Applications Act; H.R. 1262 - Mikayla Naylon Give Kids a Chance Act. Country of Origin labeling.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":27658,"prefix":null,"prefix_display":null,"first_name":"BRUCE","nickname":null,"middle_name":null,"last_name":"MEHLMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":5659,"prefix":null,"prefix_display":null,"first_name":"DEAN","nickname":null,"middle_name":null,"last_name":"ROSEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":7381,"prefix":"mr","prefix_display":"MR.","first_name":"DAVID","nickname":null,"middle_name":"R","last_name":"THOMAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":11329,"prefix":null,"prefix_display":null,"first_name":"ELISE","nickname":null,"middle_name":null,"last_name":"FINLEY PICKERING","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":61179,"prefix":null,"prefix_display":null,"first_name":"SAGE","nickname":null,"middle_name":null,"last_name":"EASTMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62201,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"ARONSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62279,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"ROBINSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":69162,"prefix":null,"prefix_display":null,"first_name":"HELEN","nickname":null,"middle_name":null,"last_name":"TOLAR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70218,"prefix":null,"prefix_display":null,"first_name":"NICHOLE","nickname":null,"middle_name":null,"last_name":"DISTEFANO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71503,"prefix":null,"prefix_display":null,"first_name":"PAUL","nickname":null,"middle_name":null,"last_name":"THORNELL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":101897,"prefix":null,"prefix_display":null,"first_name":"STEPHEN","nickname":null,"middle_name":"M.","last_name":"COTE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":101395,"prefix":null,"prefix_display":null,"first_name":"ALEXANDER","nickname":null,"middle_name":null,"last_name":"PERKINS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":101614,"prefix":null,"prefix_display":null,"first_name":"ROSEMARY","nickname":null,"middle_name":null,"last_name":"GUTIERREZ","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107920,"prefix":null,"prefix_display":null,"first_name":"ZACHARY","nickname":null,"middle_name":null,"last_name":"MALLOVE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141084,"prefix":null,"prefix_display":null,"first_name":"CAITLIN","nickname":null,"middle_name":null,"last_name":"VAN SANT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141085,"prefix":null,"prefix_display":null,"first_name":"LISA","nickname":null,"middle_name":null,"last_name":"GOLDMAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144745,"prefix":null,"prefix_display":null,"first_name":"ALYENE","nickname":null,"middle_name":null,"last_name":"MLINAR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145248,"prefix":"ms","prefix_display":"MS.","first_name":"ERICA","nickname":null,"middle_name":"JAY","last_name":"CHABOT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146767,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOLF","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147548,"prefix":null,"prefix_display":null,"first_name":"NAVEEN","nickname":null,"middle_name":null,"last_name":"PARMAR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149379,"prefix":null,"prefix_display":null,"first_name":"JON","nickname":null,"middle_name":null,"last_name":"ADAME","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151069,"prefix":"mr","prefix_display":"MR.","first_name":"JOSEPH","nickname":null,"middle_name":"EDWARD","last_name":"BROWN","suffix":"iii","suffix_display":"III"},"covered_position":null,"new":false},{"lobbyist":{"id":152223,"prefix":null,"prefix_display":null,"first_name":"EARL","nickname":null,"middle_name":"SCOTT","last_name":"FLOOD","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/7395a9aa-1397-4a8b-974b-c625b5df2d83/","filing_uuid":"7395a9aa-1397-4a8b-974b-c625b5df2d83","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/7395a9aa-1397-4a8b-974b-c625b5df2d83/print/","filing_document_content_type":"text/html","income":null,"expenses":"390000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jonathan McPherson","dt_posted":"2026-04-20T12:55:38-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"500 Warren Corporate Center Drive","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Warren","registrant_state":"NJ","registrant_zip":"07059","registrant":{"id":401105813,"url":"https://lda.gov/api/v1/registrants/401105813/","house_registrant_id":44917,"name":"PTC THERAPEUTICS, INC.","description":"Biopharmaceutical therapies for rare pediatric diseases","address_1":"100 Corporate Court","address_2":null,"address_3":null,"address_4":null,"city":"South Plainfield","state":"NJ","state_display":"New Jersey","zip":"07080","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JONATHAN MCPHERSON","contact_telephone":"+1 202-887-1400","dt_updated":"2026-07-28T16:26:17.065778-04:00"},"client":{"id":207267,"url":"https://lda.gov/api/v1/clients/207267/","client_id":12,"name":"PTC THERAPEUTICS, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-08-24"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public Law No. 117-169 -The Inflation Reduction Act of 2022 Issues related to rare disease diagnosis and testing Issues related to alternative funding programs Issues related to the Rare Pediatric Disease Priority Review Voucher program, including H.R. 1262 - Give Kids a Chance Act of 2025 and S. 932 - Give Kids a Chance Act Issues related to Public Law No. 119-21 - The One Big Beautiful Bill Act of 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":93221,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":"REA","last_name":"MCPHERSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140946,"prefix":"mr","prefix_display":"MR.","first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"BRAUGHTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152555,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":null,"last_name":"ARGOTE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"Awareness of Aromatic L-amino acid decarboxylase deficiency (AADCD) Improving diagnostic testing for rare pediatric genetic diseases Awareness of Huntingtons Disease Awareness of Friedreichs Ataxia Awareness of Phenylketonuria Awareness of Duchenne Muscular Dystrophy","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":93221,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":"REA","last_name":"MCPHERSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140946,"prefix":"mr","prefix_display":"MR.","first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"BRAUGHTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152555,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":null,"last_name":"ARGOTE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Innovative payment methodologies for cell and gene therapies Issues related to Medicaid access across state lines Issues related to Medicaid coverage of Accelerated Approval therapies Issues related to Huntingtons Disease disability insurance access Issues related to the Medicaid Drug Rebate Program Issues related to implementation of Public Law No. 117-169 - The Inflation Reduction Act of 2022, specifically the orphan drug exemption, including H.R. 946 - The Optimizing Research Progress Hope and New Cures Act and the small molecule penalty, including H.R. 1492 - The Ensuring Pathways to Innovative Cures Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":93221,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":"REA","last_name":"MCPHERSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140946,"prefix":"mr","prefix_display":"MR.","first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"BRAUGHTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152555,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":null,"last_name":"ARGOTE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to Section 174 R&D Amortization, including H.R. 1990 - American Innovation and R&D Competitiveness Act of 2025 Issues related to the Orphan Drug Tax Credit, including H.R. 1414 - Camerons Law Issues related to international reference pricing","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140946,"prefix":"mr","prefix_display":"MR.","first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"BRAUGHTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":93221,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":"REA","last_name":"MCPHERSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152555,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":null,"last_name":"ARGOTE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to tariffs","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":93221,"prefix":null,"prefix_display":null,"first_name":"JONATHAN","nickname":null,"middle_name":"REA","last_name":"MCPHERSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140946,"prefix":"mr","prefix_display":"MR.","first_name":"NICHOLAS","nickname":null,"middle_name":null,"last_name":"BRAUGHTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152555,"prefix":null,"prefix_display":null,"first_name":"BRITTANY","nickname":null,"middle_name":null,"last_name":"ARGOTE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/1418a58b-0775-4e45-9b77-06e8109c2656/","filing_uuid":"1418a58b-0775-4e45-9b77-06e8109c2656","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/1418a58b-0775-4e45-9b77-06e8109c2656/print/","filing_document_content_type":"text/html","income":null,"expenses":"12210000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Paul J. Larsen","dt_posted":"2026-04-20T13:06:32-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"670 Maine Avenue, SW","registrant_address_2":"Suite 1000","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":31350,"url":"https://lda.gov/api/v1/registrants/31350/","house_registrant_id":30654,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","description":null,"address_1":"670 Maine Avenue, SW","address_2":"Suite 1000","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PAUL J. LARSEN","contact_telephone":"+1 202-835-3400","dt_updated":"2026-07-30T11:08:37.463508-04:00"},"client":{"id":138226,"url":"https://lda.gov/api/v1/clients/138226/","client_id":12,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4: Rescissions Act of 2025 (Public Law No. 119-28) H.R. 3944: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Department of Homeland Security Appropriations Act, 2026 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law No. 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Public Law No. 119-37) S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No. 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues Government funding policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":41615,"prefix":null,"prefix_display":null,"first_name":"RANDY","nickname":null,"middle_name":null,"last_name":"BURKHOLDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147771,"prefix":null,"prefix_display":null,"first_name":"NIELAH","nickname":null,"middle_name":null,"last_name":"TUCKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":1005,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 1574: RESTORE Patent Rights Act of 2025 H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":1005,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues SECURE Rx Act of 2026 (draft) User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149775,"prefix":null,"prefix_display":null,"first_name":"JAKE","nickname":null,"middle_name":null,"last_name":"FREED","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":1005,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147771,"prefix":null,"prefix_display":null,"first_name":"NIELAH","nickname":null,"middle_name":null,"last_name":"TUCKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62437,"prefix":null,"prefix_display":null,"first_name":"SYLVIA","nickname":null,"middle_name":null,"last_name":"YU","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) S. 1637: MVP Act Inflation Reduction Act of 2022 (Public Law No. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41615,"prefix":null,"prefix_display":null,"first_name":"RANDY","nickname":null,"middle_name":null,"last_name":"BURKHOLDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149775,"prefix":null,"prefix_display":null,"first_name":"JAKE","nickname":null,"middle_name":null,"last_name":"FREED","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":1005,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147771,"prefix":null,"prefix_display":null,"first_name":"NIELAH","nickname":null,"middle_name":null,"last_name":"TUCKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62437,"prefix":null,"prefix_display":null,"first_name":"SYLVIA","nickname":null,"middle_name":null,"last_name":"YU","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues US-UK Framework Agreement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":1005,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"TILTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/a80b2b24-ba49-4e81-90b4-f4f1cd0ff9b5/","filing_uuid":"a80b2b24-ba49-4e81-90b4-f4f1cd0ff9b5","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/a80b2b24-ba49-4e81-90b4-f4f1cd0ff9b5/print/","filing_document_content_type":"text/html","income":null,"expenses":"420000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Amanda Malakoff","dt_posted":"2026-04-20T14:28:54-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3160 Porter Drive","registrant_address_2":"Suite 250","registrant_different_address":false,"registrant_city":"Palo Alto","registrant_state":"CA","registrant_zip":"94304","registrant":{"id":401107898,"url":"https://lda.gov/api/v1/registrants/401107898/","house_registrant_id":56231,"name":"BRIDGEBIO PHARMA, INC.","description":null,"address_1":"3160 Porter Drive","address_2":"Suite 250","address_3":null,"address_4":null,"city":"Palo Alto","state":"CA","state_display":"California","zip":"94304","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"AMANDA MALAKOFF","contact_telephone":"+1 202-543-8345","dt_updated":"2026-07-30T07:35:35.104836-04:00"},"client":{"id":57334,"url":"https://lda.gov/api/v1/clients/57334/","client_id":57334,"name":"BRIDGEBIO PHARMA, INC.","general_description":"Biotech company","client_government_entity":null,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2023-10-11"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"H.R.7148 - Consolidated Appropriations Act, 2026 Give Kids a Chance Act of 2025 - H.R. 1262; S 932 Orphan drug policies General issues and provisions related to PBM Reform","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144139,"prefix":null,"prefix_display":null,"first_name":"AMANDA","nickname":null,"middle_name":null,"last_name":"MALAKOFF","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154861,"prefix":"mr","prefix_display":"MR.","first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"ADAMS","suffix":"iii","suffix_display":"III"},"covered_position":"Staff Assistant and Legislative Correspondent for Sen. Johnny Isakson; Legislative Correspondent for Sen. Kelly Loeffler; Health Research Assistant and Staff Member for the Senate Health, Education, Labor and Pensions Committee.","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/0ee9221a-34ea-4846-8bd1-7b6b9b152320/","filing_uuid":"0ee9221a-34ea-4846-8bd1-7b6b9b152320","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/0ee9221a-34ea-4846-8bd1-7b6b9b152320/print/","filing_document_content_type":"text/html","income":null,"expenses":"220000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Charles Solley","dt_posted":"2026-04-20T15:02:48-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"700 CHILDREN'S DRIVE","registrant_address_2":"ADMINISTRATION","registrant_different_address":false,"registrant_city":"COLUMBUS","registrant_state":"OH","registrant_zip":"43205","registrant":{"id":309550,"url":"https://lda.gov/api/v1/registrants/309550/","house_registrant_id":38573,"name":"NATIONWIDE CHILDREN'S HOSPITAL, INC.","description":null,"address_1":"700 CHILDREN'S DRIVE","address_2":"ADMINISTRATION","address_3":null,"address_4":null,"city":"COLUMBUS","state":"OH","state_display":"Ohio","zip":"43205","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHARLIE SOLLEY","contact_telephone":"+1 614-722-5798","dt_updated":"2026-08-28T11:02:14.251737-04:00"},"client":{"id":183374,"url":"https://lda.gov/api/v1/clients/183374/","client_id":12,"name":"NATIONWIDE CHILDREN'S HOSPITAL INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"OH","state_display":"Ohio","country":"US","country_display":"United States of America","ppb_state":"OH","ppb_state_display":"Ohio","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-13"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"HR 7148 Consolidated Appropriations Act, 2026 HCR14-Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R.1 One Big Beautiful Bill Act H.R. 3302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71060,"prefix":null,"prefix_display":null,"first_name":"CHARLIE","nickname":null,"middle_name":null,"last_name":"SOLLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":70996,"prefix":null,"prefix_display":null,"first_name":"AILEEN","nickname":null,"middle_name":null,"last_name":"COLLINS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"HR 7148 Consolidated Appropriations Act, 2026 HCR14-Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R.1 One Big Beautiful Bill Act H.R. 3302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71060,"prefix":null,"prefix_display":null,"first_name":"CHARLIE","nickname":null,"middle_name":null,"last_name":"SOLLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":70996,"prefix":null,"prefix_display":null,"first_name":"AILEEN","nickname":null,"middle_name":null,"last_name":"COLLINS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/0ee9221a-34ea-4846-8bd1-7b6b9b152320/","filing_uuid":"0ee9221a-34ea-4846-8bd1-7b6b9b152320","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/0ee9221a-34ea-4846-8bd1-7b6b9b152320/print/","filing_document_content_type":"text/html","income":null,"expenses":"220000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Charles Solley","dt_posted":"2026-04-20T15:02:48-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"700 CHILDREN'S DRIVE","registrant_address_2":"ADMINISTRATION","registrant_different_address":false,"registrant_city":"COLUMBUS","registrant_state":"OH","registrant_zip":"43205","registrant":{"id":309550,"url":"https://lda.gov/api/v1/registrants/309550/","house_registrant_id":38573,"name":"NATIONWIDE CHILDREN'S HOSPITAL, INC.","description":null,"address_1":"700 CHILDREN'S DRIVE","address_2":"ADMINISTRATION","address_3":null,"address_4":null,"city":"COLUMBUS","state":"OH","state_display":"Ohio","zip":"43205","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHARLIE SOLLEY","contact_telephone":"+1 614-722-5798","dt_updated":"2026-08-28T11:02:14.251737-04:00"},"client":{"id":183374,"url":"https://lda.gov/api/v1/clients/183374/","client_id":12,"name":"NATIONWIDE CHILDREN'S HOSPITAL INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"OH","state_display":"Ohio","country":"US","country_display":"United States of America","ppb_state":"OH","ppb_state_display":"Ohio","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-13"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"HR 7148 Consolidated Appropriations Act, 2026 HCR14-Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R.1 One Big Beautiful Bill Act H.R. 3302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71060,"prefix":null,"prefix_display":null,"first_name":"CHARLIE","nickname":null,"middle_name":null,"last_name":"SOLLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":70996,"prefix":null,"prefix_display":null,"first_name":"AILEEN","nickname":null,"middle_name":null,"last_name":"COLLINS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"HR 7148 Consolidated Appropriations Act, 2026 HCR14-Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R.1 One Big Beautiful Bill Act H.R. 3302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71060,"prefix":null,"prefix_display":null,"first_name":"CHARLIE","nickname":null,"middle_name":null,"last_name":"SOLLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":70996,"prefix":null,"prefix_display":null,"first_name":"AILEEN","nickname":null,"middle_name":null,"last_name":"COLLINS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/7b9e1d37-641f-4f2c-ae00-a3b29a0f82d5/","filing_uuid":"7b9e1d37-641f-4f2c-ae00-a3b29a0f82d5","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/7b9e1d37-641f-4f2c-ae00-a3b29a0f82d5/print/","filing_document_content_type":"text/html","income":null,"expenses":"480000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Melissa Banashak","dt_posted":"2026-04-20T15:39:45-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1801 Augustine Cut-Off","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Wilmington","registrant_state":"DE","registrant_zip":"19803","registrant":{"id":401105844,"url":"https://lda.gov/api/v1/registrants/401105844/","house_registrant_id":null,"name":"INCYTE CORPORATION","description":"Biopharmaceutical Company","address_1":"1801 Augustine Cut-Off","address_2":null,"address_3":null,"address_4":null,"city":"Wilmington","state":"DE","state_display":"Delaware","zip":"19803","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MELISSA BANASHAK","contact_telephone":"+1 202-379-8022","dt_updated":"2026-07-28T17:00:17.422432-04:00"},"client":{"id":207939,"url":"https://lda.gov/api/v1/clients/207939/","client_id":12,"name":"INCYTE CORPORATION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DE","state_display":"Delaware","country":"US","country_display":"United States of America","ppb_state":"DE","ppb_state_display":"Delaware","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-01-01"},"lobbying_activities":[{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 946 / S. 1862, Orphan Cures Act implementation H.R. 1262 Give Kids a Chance Act Issues related to Medicaid rebates Issues related to implementation of the Inflation Reduction Act Issues related to the 340B Drug Pricing Program Issues related to drug cost and pricing Education around access to innovative therapies in dermatology","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":140710,"prefix":"ms","prefix_display":"MS.","first_name":"MELISSA","nickname":null,"middle_name":"WIER","last_name":"BANASHAK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":148415,"prefix":null,"prefix_display":null,"first_name":"JENNIFER","nickname":null,"middle_name":null,"last_name":"BARBLAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/a229bfd0-5906-4e09-949f-3e2dab8d1b73/","filing_uuid":"a229bfd0-5906-4e09-949f-3e2dab8d1b73","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/a229bfd0-5906-4e09-949f-3e2dab8d1b73/print/","filing_document_content_type":"text/html","income":null,"expenses":"2030000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Parrish","dt_posted":"2026-04-20T17:37:48-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"801 Pennsylvania Ave., NW Suite 900","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":5632,"url":"https://lda.gov/api/v1/registrants/5632/","house_registrant_id":31257,"name":"BAYER CORPORATION (CONSOLIDATED REPORT)","description":null,"address_1":"801 Pennsylvania Ave., NW Suite 900","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL PARRISH","contact_telephone":"+1 202-737-8900","dt_updated":"2026-07-30T15:08:38.983388-04:00"},"client":{"id":107401,"url":"https://lda.gov/api/v1/clients/107401/","client_id":12,"name":"BAYER CORPORATION (CONSOLIDATED REPORT)","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-10"},"lobbying_activities":[{"general_issue_code":"TAR","general_issue_code_display":"Tariff (miscellaneous tariff bills)","description":"Monitor and engage on legislative and administrative action related to Miscellaneous Tariff Bill (MTB) petitions. Monitor and engage on legislative and administrative action related to Section 301 tariffs. Monitor and engage on legislative and administrative action related to tariff deferment. Monitor and engage on legislative and administrative action related to tariff suspensions.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71414,"prefix":null,"prefix_display":null,"first_name":"JIM","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"AGR","general_issue_code_display":"Agriculture","description":"Monitor and engage on legislative and administrative action related to pollinator health and habitat promotion. Monitor and engage on legislative and administrative action related to Federal Insecticide, Fungicide, Rodenticide (FIFRA) Regulations. Monitor and engage on legislative and administrative action related to the Endangered Species Act and related reforms. Monitor and engage on legislative and administrative action related to 7 CFR Part 340. Monitor and engage on the implementation of the National Bioengineered Food Disclosure Law (P.L. 114-216). Monitor and engage on legislative and administrative action related to biotech innovation and regulation. Monitor and engage on legislative and administrative action related to international adoption of DNA marker evidence for plant variety protection patent. Monitor and engage on legislative and administrative action related to the programs of the Natural Resources Conservation Service (NRCS). Monitor and engage on legislative and administrative action related to food security and nutrition. Monitor and engage on legislative and administrative action related to biofuels, including ethanol, the RFS, and sustainable aviation fuel. Monitor and engage on legislative and administrative action related to Pesticides: Exemptions of Certain Plant-Incorporated Protectants Derived from Newer Technologies (Final Rule). Monitor and engage on legislative and administrative action related to reauthorization of Foundation for Food and Agriculture Research (FFAR). Monitor and engage on legislative and administrative action related to the Farm Bill reauthorization. Monitor and engage on legislative and administrative action related to Ag chemistry. Monitor and engage on legislative and administrative action related to the uniformity of pesticide labeling. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on the implementation of One Big Beautiful Bill Act (Pub. Law. 119-21). H.R. 7567, Farm, Food and National Security Act of 2026, including Section 10205 -- Uniformity of Pesticide Labeling Requirements. S. 3122, Better Food Disclosure Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71414,"prefix":null,"prefix_display":null,"first_name":"JIM","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":15,"name":"Council on Environmental Quality (CEQ)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Monitor and engage on legislative and federal activity related to tax reform. Monitor and engage on legislative and administrative action related to implementation of P.L. 115-97, Tax Cuts and Jobs Act. Monitor and engage on legislative and administrative action related to including dietary supplements as reimbursable expenses in tax-preferred savings accounts. Monitor and engage on legislative and administrative issues related to foreign tax credit regulations. Monitor and engage on the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169), including the section 45Z tax credit and the sustainable aviation fuel tax credit. Monitor and engage on the implementation of One Big Beautiful Bill Act (Pub. Law. 119-21).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62033,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"NAGLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Monitor and engage on legislative and administrative action on appropriations and budget. Monitor and engage on legislative and administrative action related to the uniformity of pesticide labeling. Monitor and engage on legislative and administrative action related to FY2027 Interior, Environment, and Related Agencies Appropriations Acts. Monitor and engage on legislative and administrative action related to FY2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Acts. H.Con.Res. 14, Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R. 4754, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2026. H.R. 5371, Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026. H.R. 6938, Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026. S. 2431, Department of the Interior, Environment, and Related Agencies Appropriations Act, 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62033,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"NAGLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71414,"prefix":null,"prefix_display":null,"first_name":"JIM","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Monitor and engage on legislative and administrative action related to intellectual property protection. Monitor and engage on legislative and administrative action related to 35 USC 101 reform.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62033,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"NAGLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Monitor and engage on legislative and administrative action related to health care policy. Monitor and engage on legislative and administrative action related to womens health issues. Monitor and engage on legislative and administrative action related to over-the-counter consumer care products. Monitor and engage on legislative and administrative action related to dietary supplements, including purchasing through HSA funds. Monitor and engage on legislative and administrative action related to servicing of medical device equipment. Monitor and engage on legislative and administrative action related to FDA monograph reform and user fees. Monitor and engage on legislative and administrative action related to the switch of prescription medications to over-the-counter medications. Monitor and engage on legislative and administrative action related to drug pricing, including rulemakings at HHS. Monitor and engage on legislative and administrative action related to 340B drug discount program. Monitor and engage on legislative and administrative action related to drug supply chain issues, including pharmacy benefit manager (PBM) reform. Monitor and engage on legislative and administrative action related to copay assistance. Monitor and engage on legislative and administrative action related to the Supplemental Nutrition Assistance Program (SNAP). Monitor and engage on legislative and administrative action related to long-acting reversable contraception usage. Monitor and engage on legislative and administrative action related to access to treatments for kidney patients. Monitor and engage on legislative and administrative action related to broader insurance coverage of supplemental imaging procedures for women with dense breast tissue. Monitor and engage on legislative and administrative action related to phenylephrine. Monitor and engage on legislative and administrative action related to e-labeling. Monitor and engage on legislative and administrative action related to DEA-determined pseudoephedrine quotas. Monitor and engage on legislative and administrative action related to Make America Healthy Again (MAHA). Monitor and engage on legislative and administrative action related to generally recognized as safe (GRAS) rules for food additives. H.R. 1262, Give Kids a Chance Act of 2025. H.R. 7366, Dietary Supplement Regulatory Uniformity Act. S. 932, Give Kids a Chance Act of 2025. S. 3677, Dietary Supplement Listing Act of 2026.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62033,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"NAGLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Monitor and engage on legislative and administrative action related to Medicare and Medicaid policy. Monitor the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169). H.R. 1492, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":62033,"prefix":null,"prefix_display":null,"first_name":"BRIAN","nickname":null,"middle_name":null,"last_name":"NAGLE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Monitor and engage on legislative and administrative action related to trade. Monitor and engage on legislative and administrative action related to foreign regulation of chemicals, pesticides, pharmaceuticals, and health care products. Monitor and engage on legislative and administrative action related to China import approvals, and foreign direct investment prohibitions and restrictions. Monitor and engage in administrative action related to maximum residue levels (MRLs) in the ASEAN region. Monitor and engage on legislative and administrative action related to foreign agriculture laws, regulations, and trade. Monitor and engage on legislative and administrative action related to investigation of Sections 232 and 301 of the Trade Act of 1974. Monitor and engage on legislative and administrative action related to the renegotiation of the United States-Korea Free Trade Agreement (KORUS FTA). Monitor and engage on legislative and administrative action related to intellectual property issues and regulations in India. Monitor and engage on legislative and administrative action related to World Trade Organization (WTO) digital trade rules. Monitor and engage on legislative and administrative action related to Section 301 tariffs. Monitor and engage on legislative and administrative action related to Section 232 tariffs. Monitor and engage on legislative and administrative action related to IEEPA tariffs.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":71414,"prefix":null,"prefix_display":null,"first_name":"JIM","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":201,"name":"Homeland Security, Dept of (DHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":16,"name":"Natl Security Council (NSC)"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":39,"name":"State, Dept of (DOS)"},{"id":41,"name":"Treasury, Dept of"},{"id":196,"name":"U.S. Agency for International Development (USAID)"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"ENG","general_issue_code_display":"Energy/Nuclear","description":"Monitor and engage on legislative and administrative action related to Biofuels and the Renewable Fuel Standard. Monitor and engage on the implementation of the Infrastructure Investment and Jobs Act (P.L. 117-58). Monitor and engage on the implementation of the Inflation Reduction Act of 2022 (P.L. 117-169).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"NAT","general_issue_code_display":"Natural Resources","description":"Monitor and engage on legislative and administrative action related to phosphate mining operations and permits. Monitor and engage on legislative and administrative action related to Caldwell Canyon permitting. Monitor and engage on legislative and administrative action related to proposed Conservation and Landscape Health Rule and Greater Sage Grouse Habitat Conservation Plans. Monitor and engage on legislative and administrative action related to the Endangered Species Act. Monitor and engage regarding the inclusion of glyphosate on the critical minerals list. Monitor and engage on legislative and administrative action related to the Fairness and Certainty in Reclamation Act (no bill number yet). H.R. 1897, ESA Amendments Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":148,"name":"Bureau of Land Management (BLM)"},{"id":49,"name":"Environmental Protection Agency (EPA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":36,"name":"Interior, Dept of (DOI)"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":144,"name":"U.S. Geological Survey (USGS)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"ENV","general_issue_code_display":"Environment/Superfund","description":"Monitor and engage on legislative and administrative action related to climate change, including sustainable agriculture. Monitor and engage on legislative and administrative action related to FIFRA Regulations, including voluntary carbon markets. Monitor and engage on legislative and administrative action related to the Endangered Species Act. H.R. 1897, ESA Amendments Act of 2025.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"Monitor and engage on legislative and administrative action related to antitrust and competition.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70509,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"HOLLAND","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70512,"prefix":null,"prefix_display":null,"first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"PARRISH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70513,"prefix":null,"prefix_display":null,"first_name":"STEPHANIE","nickname":null,"middle_name":null,"last_name":"MURPHY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142398,"prefix":null,"prefix_display":null,"first_name":"ERICK","nickname":null,"middle_name":null,"last_name":"LUTT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":23,"name":"Agriculture, Dept of (USDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"FOR","general_issue_code_display":"Foreign Relations","description":"Resolution expressing a commitment to strengthen science, technology, and innovation R&D for economic development in Africa, and the importance for US engagement with Africa to address global challenges.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71414,"prefix":null,"prefix_display":null,"first_name":"JIM","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/66175b7e-e50c-417e-9b59-fe983232a2aa/","filing_uuid":"66175b7e-e50c-417e-9b59-fe983232a2aa","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/66175b7e-e50c-417e-9b59-fe983232a2aa/print/","filing_document_content_type":"text/html","income":null,"expenses":"80000.00","expenses_method":"B","expenses_method_display":"B","posted_by_name":"Laura Weidner","dt_posted":"2026-04-20T20:40:49-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3540 Crain Highway","registrant_address_2":"Ste. 675","registrant_different_address":true,"registrant_city":"Bowie","registrant_state":"MD","registrant_zip":"20716","registrant":{"id":13723,"url":"https://lda.gov/api/v1/registrants/13723/","house_registrant_id":33344,"name":"EPILEPSY FOUNDATION","description":null,"address_1":"3540 Crain Highway","address_2":"Ste. 675","address_3":null,"address_4":null,"city":"Bowie","state":"MD","state_display":"Maryland","zip":"20716","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"LAURA WEIDNER","contact_telephone":"+1 301-918-3766","dt_updated":"2026-07-20T13:55:01.108310-04:00"},"client":{"id":119125,"url":"https://lda.gov/api/v1/clients/119125/","client_id":12,"name":"EPILEPSY FOUNDATION","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"MD","state_display":"Maryland","country":"US","country_display":"United States of America","ppb_state":"MD","ppb_state_display":"Maryland","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-07-18"},"lobbying_activities":[{"general_issue_code":"EDU","general_issue_code_display":"Education","description":"-Department of Education, oppose Reductions of Force at and changes to (including moving sections of) the Dept. of Education that could impede the rights of students with disabilities -S. 3448/H.R. 6617, Keeping All Students Safe Act, support passage","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":144397,"prefix":null,"prefix_display":null,"first_name":"ROXANNE","nickname":null,"middle_name":null,"last_name":"YAGHOUBI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139463,"prefix":"mr","prefix_display":"MR.","first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"BECK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":32,"name":"Education, Dept of"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"-Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2026, support funding for epilepsy programs and research including $11.581 billion for the CDC including $11.5 million for the CDCs Epilepsy program and $164 million for the CDCs Safe Motherhood and Infant Health Program, at least $48.7 billion for the NIH, $680 million for the BRAIN Initiative, and increased funding for the Social Security Administration. -Labor, Health and Human Services, Education and Related Agencies Appropriations Act, 2027, support funding for epilepsy programs and research including $11.581 billion for the CDC including $11.5 million for the CDCs Epilepsy program and $164 million for the CDCs Safe Motherhood and Infant Health Program; language supporting a report about establishing a National Plan for Epilepsy; at least $51.303 billion for the NIH and $468 million for the BRAIN Initiative; increased funding for the Social Security Administration; and language supporting a report about how the newborn screening evidence-based review process will continue to be implemented and language clarifying that Title V can fund state-sponsored genetic screening pilot programs. -Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2027, support at least $29 million for the VA Epilepsy Centers of Excellence. -Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2027, support robust funding for the Food & Drug Administration -Defense Appropriations Act, 2026, within the Congressionally Directed Medical Research Programs, support $12 million for the Epilepsy Program, $10 million for the Tuberous Sclerosis Complex program and $175 million for the TBI and Psychological Health Program. -Defense Appropriations Act, 2027, within the Congressionally Directed Medical Research Programs, support $12 million for the Epilepsy Program, $12 million for the Tuberous Sclerosis Complex program and $175 million for the TBI and Psychological Health Program. -Commerce, Justice, Science Appropriations Act, 2026, oppose provisions that could restrict access to CBD and block rescheduling","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69712,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"WEIDNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139463,"prefix":"mr","prefix_display":"MR.","first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"BECK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144397,"prefix":null,"prefix_display":null,"first_name":"ROXANNE","nickname":null,"middle_name":null,"last_name":"YAGHOUBI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"-P.L. 119-21, Support policies and processes that reduce the impact of the cuts and changes to Medicaid on people with serious and chronic conditions, people with disabilities, and caregivers -S. 494/H.R. 1189, National Plan for Epilepsy Act, support passage -Requests to join the Congressional Epilepsy Caucus -S. 2903/H.R. 5509, Safe Step Act, support passage -S. 864/H.R. 6423, HELP Copays Act, support passage -S. 932/ H.R. 1262, Give Kids A Chance Act, support reauthorization of the Rare Pediatric Disease Review Voucher -WISeR Model, express concern with how it could impede access to some epilepsy treatments -PBM Reform, support passage and the inclusion of patient-centric policies -Medicare Part Ds Six Protected Classes policy, support coverage of and access to all epilepsy treatments and express concerns with the impact of the GUARD Model on the Six Protected Classes policy. -Enhanced Advance Premium Tax Credits, support reauthorization. -Medicare Part D out-of-pocket cap and the Medicare Prescription Payment Plan, support patient-centric implementation -ACA marketplace rule, express concerns that changes will decrease enrollment and increase costs -Telehealth, support extensions of telehealth flexibilities including the prescribing of epilepsy medications that are controlled substances -S. 1024/H.R. 2151, Seizure Awareness and Preparedness Act, support passage -S. 752/H.R. 1509, Accelerating Kids Access to Care Act, support passage -U.S. Department of Health and Human Services (HHS), support protecting the current structure of HHS and express concerns with HHS staffing changes and cuts -NIH, support the current structure, current facilities and administrative cost structure, and grantmaking process of the NIH; express concerns with leadership and staffing changes and an expansion of multiyear funding -Support programs that assist caregivers -Oppose legislative or regulatory policies that rely on metrics like Quality-Adjusted Life Years -Support rescheduling and safe and legal access to medical cannabis -S. 1816/ H.R. 3514, Improving Seniors Timely Access to Care Act, support passage -S. 455/H.R. 1061, Protecting Sensitive Locations Act, support passage -Oppose legislation that would weaken the Affordable Care Act protections, including H.R. 2528, Association Health Plans Act and H.R. 2571, Self-Insurance Protection Act -Express concerns with legislative and regulatory policies that would restrict the use of animals in research -Support legislation and policy preserving charitable giving including the Combined Federal Campaign -H.R. 6280, Access to Genetic Counselor Services Act, support passage -Support legislation and regulations that protect Medicaid Home- and Community-Based Services (HCBS) and increase access to these services","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":69712,"prefix":null,"prefix_display":null,"first_name":"LAURA","nickname":null,"middle_name":null,"last_name":"WEIDNER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139463,"prefix":"mr","prefix_display":"MR.","first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"BECK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144397,"prefix":null,"prefix_display":null,"first_name":"ROXANNE","nickname":null,"middle_name":null,"last_name":"YAGHOUBI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":139,"name":"Natl Institutes of Health (NIH)"},{"id":1,"name":"SENATE"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"}]},{"general_issue_code":"CIV","general_issue_code_display":"Civil Rights/Civil Liberties","description":"-FAA reauthorization, support implementation of disability provisions -Surface Transportation Reauthorization, support inclusion of disability and accessibility provisions -Autonomous vehicle legislation, support the inclusion of disability and accessibility provisions","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":139463,"prefix":"mr","prefix_display":"MR.","first_name":"TYLER","nickname":null,"middle_name":null,"last_name":"BECK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144397,"prefix":null,"prefix_display":null,"first_name":"ROXANNE","nickname":null,"middle_name":null,"last_name":"YAGHOUBI","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":172,"name":"Federal Aviation Administration (FAA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":40,"name":"Transportation, Dept of (DOT)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/2c5d0123-1385-41b5-aa02-7303db5efcbf/","filing_uuid":"2c5d0123-1385-41b5-aa02-7303db5efcbf","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/2c5d0123-1385-41b5-aa02-7303db5efcbf/print/","filing_document_content_type":"text/html","income":null,"expenses":"1640000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Brent Fisk","dt_posted":"2026-04-20T21:36:54-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 F STREET, NW, #480","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":16293,"url":"https://lda.gov/api/v1/registrants/16293/","house_registrant_id":31461,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","description":"PHARMACEUTICALS","address_1":"1201 F STREET, NW, #480","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BRENT FISK","contact_telephone":"+1 703-501-8920","dt_updated":"2026-10-05T10:48:35.722200-04:00"},"client":{"id":121722,"url":"https://lda.gov/api/v1/clients/121722/","client_id":12,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-04-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4: Rescissions Act of 2025 (P.L. 119-28) H.R. 3944: Military Construction, Veterans Affairs, and Related Agencies Appropriations Act, 2026 H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 4213: Department of Homeland Security Appropriations Act, 2026 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (P.L. 119-74) S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Public Law 119-37) S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No: 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75), Provisions related to the pharmaceutical industry. Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Government funding policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 1574: RESTORE Patent Rights Act of 2025 H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 932: Give Kids a Chance Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: H.R. 1492, Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025. To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues MAHA Commission Report - Make Our Children Healthy Again Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Section 340B Public Health Services Act 340B engagement and MFN related engagement Provisions related to the 340B program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues S. 5459: Biosimilars Access and Affordability Act (118th Congress) Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Presidential Memoranda: Memorandum for the Secretary of Health and Human Services the Commissioner of Drugs - Addressing Misleading Direct-to-Consumer Prescription Drug Advertisements Biopharmaceutical innovation and pricing issues HR 5509, Safe Step Act, Provisions related step therapy protocols Tariff and MFN issues VICP Bill","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) S. 1637: MVP Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues China outbound investment policy issues US-UK Framework Agreement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/4ebc8da1-b3f2-4f07-89b4-e0518e9bb822/","filing_uuid":"4ebc8da1-b3f2-4f07-89b4-e0518e9bb822","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/4ebc8da1-b3f2-4f07-89b4-e0518e9bb822/print/","filing_document_content_type":"text/html","income":null,"expenses":"47670.00","expenses_method":"C","expenses_method_display":"C","posted_by_name":"Steve Issenman","dt_posted":"2026-07-15T11:58:56-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"10 W. Lafayette Street","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"Trenton","registrant_state":"NJ","registrant_zip":"08608","registrant":{"id":75251,"url":"https://lda.gov/api/v1/registrants/75251/","house_registrant_id":36035,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","description":"government affairs for biopharmaceutical and medical device trade association","address_1":"10 W. Lafayette Street","address_2":null,"address_3":null,"address_4":null,"city":"Trenton","state":"NJ","state_display":"New Jersey","zip":"08608","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"STEVE ISSENMAN","contact_telephone":"+1 732-729-9619","dt_updated":"2026-07-15T15:26:57.674024-04:00"},"client":{"id":167699,"url":"https://lda.gov/api/v1/clients/167699/","client_id":12,"name":"HEALTHCARE INSTITUTE OF NEW JERSEY","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"NJ","state_display":"New Jersey","country":"US","country_display":"United States of America","ppb_state":"NJ","ppb_state_display":"New Jersey","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2008-12-08"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Generally promoting awareness of the biopharmaceutical and medical technology sectors. Generally opposing the imposition of price controls in the Medicare Part D program or elsewhere. Generally supporting intellectual property rights. Generally opposing various legislative and executive efforts to impose an international price index. Generally promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the extension of the SBIR program. Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1414). Supporting the modernization of prescribing information to allow digital in lieu of printed information, H.R. 4132 and S. 2027. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET (H.R. 1691 in the previous Congress). Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369 in the previous Congress). Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 in the previous Congress). Supporting the Protecting Patients Against PBM Abuses Act (H.R. 2880 in the previous Congress). Supporting the PASTEUR Act (H.R. 2940 and S. 1355 in the previous Congress). Supporting the Treat And Reduce Obesity Act (H.R. 4818, S. 2407 in the previous Congress). Supporting the Protecting Patient Access to Cancer and Complex Therapies Act (H.R. 5391 and S. 2764 in the previous Congress). Supporting the Rare Pediatric Disease Priority Review Voucher Act (H.R. 1262 and S. 932). Supporting the Maintaining Investments in New Innovation (MINI) Act (H.R. 1672). Supporting the Delinking Revenue from Unfair Gouging (DRUG) Act (H.R. 6283 in the previous Congress). Supporting changes to the small molecule portions of the Inflation Reduction Act (H.R. 1492 and S. 832). Supporting \"cap and smooth\" efforts within the Inflation Reduction Act's cap on out-of-pocket expenses. Opposing pricing policies related to \"Most Favored Nation\" proposals and indexing to international prices. Opposing tariffs on pharmaceutical and medical device products. Opposing CMSs proposed interpretation of a Qualifying Single Source Drug (QSSD). Generally providing thoughts on federal data privacy transparency and security policies. Submitting comments opposing proposed changes to bona fide fee structures. Generally opposing CMMI's demonstration project on prior authorization in the Medicare program. Supporting the RESULTS Act, HR 5269 and S.2761. Opposing CMS GUARD and GLOBE pricing model proposals. Opposing HR 3375 and S 1587, \"Most Favored Nation\" legislation. Supporting the PBM FAIR Act, H.R. 68937 and S. 3549. Generally raising awareness of vaccine efficacy.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":45619,"prefix":null,"prefix_display":null,"first_name":"STEVE","nickname":null,"middle_name":null,"last_name":"ISSENMAN","suffix":null,"suffix_display":null},"covered_position":"Cong. Page (87-88), Congressional Aide (1990's)","new":false}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/3a8014d4-59f2-44bd-8a91-fea893d0afaa/","filing_uuid":"3a8014d4-59f2-44bd-8a91-fea893d0afaa","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/3a8014d4-59f2-44bd-8a91-fea893d0afaa/print/","filing_document_content_type":"text/html","income":null,"expenses":"80000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Charles Solley","dt_posted":"2026-07-15T14:26:12-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"700 CHILDREN'S DRIVE","registrant_address_2":"ADMINISTRATION","registrant_different_address":false,"registrant_city":"COLUMBUS","registrant_state":"OH","registrant_zip":"43205","registrant":{"id":309550,"url":"https://lda.gov/api/v1/registrants/309550/","house_registrant_id":38573,"name":"NATIONWIDE CHILDREN'S HOSPITAL, INC.","description":null,"address_1":"700 CHILDREN'S DRIVE","address_2":"ADMINISTRATION","address_3":null,"address_4":null,"city":"COLUMBUS","state":"OH","state_display":"Ohio","zip":"43205","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHARLIE SOLLEY","contact_telephone":"+1 614-722-5798","dt_updated":"2026-08-28T11:02:14.251737-04:00"},"client":{"id":183374,"url":"https://lda.gov/api/v1/clients/183374/","client_id":12,"name":"NATIONWIDE CHILDREN'S HOSPITAL INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"OH","state_display":"Ohio","country":"US","country_display":"United States of America","ppb_state":"OH","ppb_state_display":"Ohio","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-13"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"HR 7148 Consolidated Appropriations Act, 2026 HCR14-Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R.1 One Big Beautiful Bill Act H.R. 3302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 H.R. 3277 Ensuring Lasting Smiles Act H.R. 9504 Tax Exempt Hospital Transparency Act H.R. 9599 SECURE 340B Act H.R. 5256 340B ACCESS ACT S. 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025 S. 1677 Ensuring Lasting Smiles Act S. 2372 340B PATIENTS Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71060,"prefix":null,"prefix_display":null,"first_name":"CHARLIE","nickname":null,"middle_name":null,"last_name":"SOLLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":70996,"prefix":null,"prefix_display":null,"first_name":"AILEEN","nickname":null,"middle_name":null,"last_name":"COLLINS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"HR 7148 Consolidated Appropriations Act, 2026 HCR14-Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R.1 One Big Beautiful Bill Act H.R. 3302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 H.R. 3277 Ensuring Lasting Smiles Act H.R. 9504 Tax Exempt Hospital Transparency Act H.R. 9599 SECURE 340B Act H.R. 5256 340B ACCESS ACT S. 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025 S. 1677 Ensuring Lasting Smiles Act S. 2372 340B PATIENTS Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71060,"prefix":null,"prefix_display":null,"first_name":"CHARLIE","nickname":null,"middle_name":null,"last_name":"SOLLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":70996,"prefix":null,"prefix_display":null,"first_name":"AILEEN","nickname":null,"middle_name":null,"last_name":"COLLINS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/3a8014d4-59f2-44bd-8a91-fea893d0afaa/","filing_uuid":"3a8014d4-59f2-44bd-8a91-fea893d0afaa","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/3a8014d4-59f2-44bd-8a91-fea893d0afaa/print/","filing_document_content_type":"text/html","income":null,"expenses":"80000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Charles Solley","dt_posted":"2026-07-15T14:26:12-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"700 CHILDREN'S DRIVE","registrant_address_2":"ADMINISTRATION","registrant_different_address":false,"registrant_city":"COLUMBUS","registrant_state":"OH","registrant_zip":"43205","registrant":{"id":309550,"url":"https://lda.gov/api/v1/registrants/309550/","house_registrant_id":38573,"name":"NATIONWIDE CHILDREN'S HOSPITAL, INC.","description":null,"address_1":"700 CHILDREN'S DRIVE","address_2":"ADMINISTRATION","address_3":null,"address_4":null,"city":"COLUMBUS","state":"OH","state_display":"Ohio","zip":"43205","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHARLIE SOLLEY","contact_telephone":"+1 614-722-5798","dt_updated":"2026-08-28T11:02:14.251737-04:00"},"client":{"id":183374,"url":"https://lda.gov/api/v1/clients/183374/","client_id":12,"name":"NATIONWIDE CHILDREN'S HOSPITAL INC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"OH","state_display":"Ohio","country":"US","country_display":"United States of America","ppb_state":"OH","ppb_state_display":"Ohio","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-13"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"HR 7148 Consolidated Appropriations Act, 2026 HCR14-Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R.1 One Big Beautiful Bill Act H.R. 3302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 H.R. 3277 Ensuring Lasting Smiles Act H.R. 9504 Tax Exempt Hospital Transparency Act H.R. 9599 SECURE 340B Act H.R. 5256 340B ACCESS ACT S. 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025 S. 1677 Ensuring Lasting Smiles Act S. 2372 340B PATIENTS Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71060,"prefix":null,"prefix_display":null,"first_name":"CHARLIE","nickname":null,"middle_name":null,"last_name":"SOLLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":70996,"prefix":null,"prefix_display":null,"first_name":"AILEEN","nickname":null,"middle_name":null,"last_name":"COLLINS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"HR 7148 Consolidated Appropriations Act, 2026 HCR14-Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appropriate budgetary levels for fiscal years 2026 through 2034. H.R.1 One Big Beautiful Bill Act H.R. 3302 Healthy Start Reauthorization Act of 2025 H.R.5371 Continuing Appropriations and Extensions Act of 2026 S. 3389 Lowering Health care Cost for Americans Act H.R. 1262 Mikaela Naylon Give Kids a Chance Act H.R. 5582 Patients Deserve Price Tags Act H.R. 5304 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 H.R. 3277 Ensuring Lasting Smiles Act H.R. 9504 Tax Exempt Hospital Transparency Act H.R. 9599 SECURE 340B Act H.R. 5256 340B ACCESS ACT S. 2587 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2026 S. 2355 Patients Deserve Price Tags Act S. 891 Bipartisan Health Care Act S. 932 Give Kids a Chance Act of 2025 S. 1677 Ensuring Lasting Smiles Act S. 2372 340B PATIENTS Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":71060,"prefix":null,"prefix_display":null,"first_name":"CHARLIE","nickname":null,"middle_name":null,"last_name":"SOLLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":70996,"prefix":null,"prefix_display":null,"first_name":"AILEEN","nickname":null,"middle_name":null,"last_name":"COLLINS","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/67b5714f-7362-43a2-86fd-22759280fe17/","filing_uuid":"67b5714f-7362-43a2-86fd-22759280fe17","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/67b5714f-7362-43a2-86fd-22759280fe17/print/","filing_document_content_type":"text/html","income":null,"expenses":"890000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Brent Fisk","dt_posted":"2026-07-16T16:09:46-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"1201 F STREET, NW, #480","registrant_address_2":null,"registrant_different_address":true,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":16293,"url":"https://lda.gov/api/v1/registrants/16293/","house_registrant_id":31461,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","description":"PHARMACEUTICALS","address_1":"1201 F STREET, NW, #480","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BRENT FISK","contact_telephone":"+1 703-501-8920","dt_updated":"2026-10-05T10:48:35.722200-04:00"},"client":{"id":121722,"url":"https://lda.gov/api/v1/clients/121722/","client_id":12,"name":"GSK (FKA GLAXOSMITHKLINE INC.)","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-04-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"Presidents Budget Fiscal Year 2027 H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 4: Rescissions Act of 2025 (Public Law 119-28) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S. ___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 9310: Department of Homeland Security Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S._____: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (P.L. 119-74) H.R. 8845: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S. ___: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law No: 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 S. 2: Secure America Act (Public Law 119-18) H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Government funding policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act S. 3452: Biological Intellectual Protection Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act HR 5509, Safe Step Act, Provisions related step therapy protocols H.R. 6423: HELP Copays Act H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7391, the Community Health Center Drug Pricing Protection Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First S. 891, Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S.4784, An original bill to authorize appropriations for fiscal year 2027 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes, Provisions related to the pharmaceutical industry. Smucker's VICP bill Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Vaccine policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1: One Big Beautiful Bill Act (Public Law No. 119-21) Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act H.R. 9102: Biotech Investment National Security Act (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":147079,"prefix":null,"prefix_display":null,"first_name":"LIAM","nickname":null,"middle_name":null,"last_name":"MACDONALD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147862,"prefix":null,"prefix_display":null,"first_name":"HARMEET","nickname":null,"middle_name":null,"last_name":"DHILLON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151996,"prefix":null,"prefix_display":null,"first_name":"BRENTON","nickname":null,"middle_name":null,"last_name":"FISK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154302,"prefix":null,"prefix_display":null,"first_name":"JASEY","nickname":null,"middle_name":null,"last_name":"CARDENAS","suffix":null,"suffix_display":null},"covered_position":"Cong. Filemon Vela, Fellow, Staff Asst/Leg Correspondent, Leg Asst. 2014-2016","new":true},{"lobbyist":{"id":154303,"prefix":null,"prefix_display":null,"first_name":"CARA","nickname":null,"middle_name":null,"last_name":"WALTHER","suffix":null,"suffix_display":null},"covered_position":"Cong. Marsha Blackburn, Intern, Sept. 2016-Dec. 2016 Cong. Devin Nunes, Intern, Jan. 2017-Feb. 2017","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/70494441-3fb4-4099-829b-ffd9b717efe3/","filing_uuid":"70494441-3fb4-4099-829b-ffd9b717efe3","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/70494441-3fb4-4099-829b-ffd9b717efe3/print/","filing_document_content_type":"text/html","income":null,"expenses":"140000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Christopher Porter","dt_posted":"2026-07-20T08:09:29-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"3611 Valley Centre Drive","registrant_address_2":"Suite 300","registrant_different_address":true,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401104190,"url":"https://lda.gov/api/v1/registrants/401104190/","house_registrant_id":null,"name":"TRAVERE THERAPEUTICS","description":"Pharmaceuticals","address_1":"3611 Valley Centre Drive","address_2":"Suite 300","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CHRISTOPHER PORTER","contact_telephone":"+1 877-969-7879","dt_updated":"2026-07-20T10:56:00.116563-04:00"},"client":{"id":200929,"url":"https://lda.gov/api/v1/clients/200929/","client_id":12,"name":"TRAVERE THERAPEUTICS","general_description":"Biopharmaceuticals","client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2016-08-15"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MED","general_issue_code_display":"Medical/Disease Research/Clinical Labs","description":"HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Saves Lives Reauthorization Act; PDUFA/regulatory review process; H.R. 9102, Biotech Investment National Security Act (BINSA)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.H.R. 9509, the Kidney Disease Education Expansion Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets. S. 2658, Medication Affordability and Patent Integrity Act","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; pharmaceutical tariffs, specifically related to orphan drugs","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":64866,"prefix":null,"prefix_display":null,"first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"PORTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141299,"prefix":null,"prefix_display":null,"first_name":"ROSE","nickname":null,"middle_name":null,"last_name":"GALLAGHER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/68974659-b5c4-49fd-9cf7-0d1ae2d9c791/","filing_uuid":"68974659-b5c4-49fd-9cf7-0d1ae2d9c791","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/68974659-b5c4-49fd-9cf7-0d1ae2d9c791/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Brian Pomper","dt_posted":"2026-07-20T09:46:50-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"2001 K St NW","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20006","registrant":{"id":682,"url":"https://lda.gov/api/v1/registrants/682/","house_registrant_id":31784,"name":"AKIN GUMP STRAUSS HAUER & FELD","description":"Law firm","address_1":"2001 K St NW","address_2":null,"address_3":null,"address_4":null,"city":"WASHINGTON","state":"DC","state_display":"District of Columbia","zip":"20006","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BRIAN POMPER","contact_telephone":"+1 202-887-4000","dt_updated":"2026-07-30T23:00:42.376033-04:00"},"client":{"id":100594,"url":"https://lda.gov/api/v1/clients/100594/","client_id":1406,"name":"BIOTECHNOLOGY INNOVATION ORGANIZATION","general_description":null,"client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2011-11-16"},"lobbying_activities":[{"general_issue_code":"SMB","general_issue_code_display":"Small Business","description":"Issues related to the Small Business Innovation Research Program in the Small Business Innovation and Economic Security Act (P.L. 119-83).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":148811,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"SCHWIETERT","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262 / S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases; Issues related to the biotech ecosystem, including most-favored-nation drug pricing; Issues related to PBM reform, PAHPA reauthorization; and PDUFA reauthorization.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":104715,"prefix":null,"prefix_display":null,"first_name":"ANNA","nickname":null,"middle_name":null,"last_name":"ABRAM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70247,"prefix":null,"prefix_display":null,"first_name":"VIRGIL","nickname":null,"middle_name":null,"last_name":"MILLER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154421,"prefix":null,"prefix_display":null,"first_name":"MARA","nickname":null,"middle_name":null,"last_name":"LEFEVRE","suffix":null,"suffix_display":null},"covered_position":"Leg. Asst., Sen. Hoeven (2025-2026); Leg. Aide, Sen. Hoeven (2025); Leg. Cor., Sen. Hoeven (2023-2024); Staff Asst., Sen. Hoeven (2022-2023); Intern, Sen. KCramer (2020).","new":true}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/5ad8f848-d4e0-4bdf-b014-99812a46595b/","filing_uuid":"5ad8f848-d4e0-4bdf-b014-99812a46595b","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/5ad8f848-d4e0-4bdf-b014-99812a46595b/print/","filing_document_content_type":"text/html","income":null,"expenses":"700000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Michael Mattoon, Vice President, Government Affairs & Policy - Acadia Pharmaceuticals","dt_posted":"2026-07-20T12:28:31-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"12830 El Camino Real","registrant_address_2":"Suite 400","registrant_different_address":false,"registrant_city":"San Diego","registrant_state":"CA","registrant_zip":"92130","registrant":{"id":401105828,"url":"https://lda.gov/api/v1/registrants/401105828/","house_registrant_id":null,"name":"ACADIA PHARMACEUTICALS","description":"Biopharmaceutical company","address_1":"12830 El Camino Real","address_2":"Suite 400","address_3":null,"address_4":null,"city":"San Diego","state":"CA","state_display":"California","zip":"92130","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"MICHAEL MATTOON","contact_telephone":"+1 615-861-6000","dt_updated":"2026-07-27T17:33:39.420897-04:00"},"client":{"id":207583,"url":"https://lda.gov/api/v1/clients/207583/","client_id":12,"name":"ACADIA PHARMACEUTICALS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-10-27"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Mikaela Naylon Give Kids A Chance Act (HR 1262), Give Kids A Chance Act (S 932), Cameron's Law (HR 1414), Kids Access to Care Act (Accelerating HR 1509, S 752), Small Biotech Innovations Act (HR 3731, S 1930), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), BINSA Act, H.R. 9102, Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267) Implementation of the Inflation Reduction Act of 2022, ORPHAN Cures Act (HR 946, S 1862), Accelerating Kids Access to Care Act (HR 1509, S 752), EPIC Act (HR 1492, S 832), One Big Beautiful Bill Act (HR 1), Issues related to protecting patient access to medicines in Medicare and Medicaid, Issues related to access to medicines for Parkinson's disease patients, Issues related to Antipsychotic use in Medicare, Issues related to most-favored-nation policies.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Cameron's Law (HR 1414), One Big Beautiful Bill Act (HR 1).","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"BINSA Act, H.R. 9102.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151391,"prefix":"ms","prefix_display":"MS.","first_name":"SARAH","nickname":null,"middle_name":"TODD","last_name":"TELLOCK","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":138768,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":null,"last_name":"MATTOON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/cb76bfb5-8577-4487-a413-a9e8b217d053/","filing_uuid":"cb76bfb5-8577-4487-a413-a9e8b217d053","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/cb76bfb5-8577-4487-a413-a9e8b217d053/print/","filing_document_content_type":"text/html","income":null,"expenses":"1410000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Courtney Piron","dt_posted":"2026-07-20T13:40:41-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"801 PENNSYLVANIA AVENUE, NW","registrant_address_2":"Suite 700","registrant_different_address":false,"registrant_city":"WASHINGTON","registrant_state":"DC","registrant_zip":"20004","registrant":{"id":9204,"url":"https://lda.gov/api/v1/registrants/9204/","house_registrant_id":33589,"name":"NOVARTIS","description":"Federal Government Relations/Legislative Affairs","address_1":"801 Pennsylvania Avenue, NW","address_2":"Suite 700","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20004","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"COURTNEY PIRON","contact_telephone":"+1 202-662-4364","dt_updated":"2026-07-22T10:55:30.763850-04:00"},"client":{"id":113305,"url":"https://lda.gov/api/v1/clients/113305/","client_id":12,"name":"NOVARTIS","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2010-12-07"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 Funding for FDA - FY 2026 Appropriations Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act 2026 FY 2026 President's Budget Request Inflation Reduction Act of 2022 (P.L. 117-169) Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 Federal Budget Funding for National Institutes of Health - FY 2026 Appropriations H.R. 1: One Big Beautiful Bill Act (P.L. 119-21) FY 2027 President's Budget H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75)","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 2276/HR. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues Patent eligibility policy issues S. 1546/H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) Restrictions on Intellectual Property Rights PTAB reform Patent fee policy issues Section 101 reform","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152665,"prefix":null,"prefix_display":null,"first_name":"NANCY","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152572,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":"ANDREW","last_name":"SUTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Direct to Consumer Advertising 340B Drug Discount Program - Program Implementation & Oversight 340B PATIENTS Act of 2024 340B Drug Discount Program - RFI for SUSTAIN 340B Act HR. 5256 - 340B Affording Care for Communities and Ensuring a Strong Safety-Net Act(340B ACCESS Act) To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program 340B drug discount program rebate and policy issues 340B rebate pilot program H.R.9504: Tax Exempt Hospital Transparency Act 340B Program Implementation & Oversight H.R. 9599 - SECURE 340B Act Accelerated Approval Breast Cancer Research H.R.3037, Access to Breast Cancer Diagnostic Act of 2025 S.1500, Access to Breast Cancer Diagnostic Act of 2025 Alternative Funding Programs Supply Chain Integrity and Traceability PBM Reform Modernizing and Ensuring PBM Accountability (MEPA) Act Coverage of Accelerated Approval Products Drug Benefit Design Orphan Drug Issues S. 1682/H.R.946: ORPHAN Cures Act S.932/H.R. 1262: Give Kids a Chance Act of 2025 Innovation in Pediatric Drugs Act S.864: HELP Copays Act Reimbursement and Coverage of Innovative Products Lower Costs, More Transparency Act Lower Costs, More Cures Act Medicare Part B Physician-Administered Products Patient Cost-Sharing and Smoothing Step Therapy Support of Patient Premiums and Cost-Sharing Obligations Value-based Contracting and Communications H.R. 2214: DRUG Act User fee policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues FDA regulatory approval authority policy issues Competition policy issues Clinical trial diversity policy issues Patient assistance program policy issues Drug shortages policy issues Artificial intelligence policy issues IRA price negotiation expansion policy issues Rare Pediatric Disease Priority Review Voucher program policies SUSTAIN RFI/discussion draft Most Favored Nation (MFN) policy Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First Utilization management policies Clinical trial data in China S.3788: CLEAR Labels Act S. 4784/H.R. 8800: National Defense Authorization Act for Fiscal Year 2027","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152665,"prefix":null,"prefix_display":null,"first_name":"NANCY","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152572,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":"ANDREW","last_name":"SUTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":137,"name":"Health Resources & Services Administration (HRSA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule H.R. 950: Saving Seniors Money on Prescriptions Act Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues S. 832/H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R.1672: Maintaining Investments in New Innovation Act or the MINI Act of 2025 Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues H.R. 5391/S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act Drug cost and pricing policy issues Medicare rebate policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":8,"name":"Congressional Budget Office (CBO)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":18,"name":"Office of Management & Budget (OMB)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Domestic and International Tax Policy Issues Research & Development Tax Credit Reforms Foreign Direct Investment Expensing of R&D Expenditures H.R. 2425 - Unfair Tax Prevention Act of 2025 Tax Cuts and Jobs Act, PL 115-97 H.R. 1: One Big Beautiful Bill Act (P.L. 119-21)","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Sec. 301 pharmaceutical tariffs US-UK Framework Agreement Tariff policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues International pharmaceutical pricing and reimbursement policy issues Supply chain policy issues China outbound investment policy issues US Swiss Trade Agreement US Trade Policy Sec. 232 pharmaceutical tariffs Pharmaceutical manufacturing policy and investment issues Outbound Investment Security Program H.R. 9102 - Biotech Investment National Security Act","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152665,"prefix":null,"prefix_display":null,"first_name":"NANCY","nickname":null,"middle_name":null,"last_name":"TRAVIS","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":152572,"prefix":"mr","prefix_display":"MR.","first_name":"THOMAS","nickname":null,"middle_name":"ANDREW","last_name":"SUTER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"LBR","general_issue_code_display":"Labor Issues/Antitrust/Workplace","description":"Anti-Trust Reform","foreign_entity_issues":"Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.","lobbyists":[{"lobbyist":{"id":66283,"prefix":null,"prefix_display":null,"first_name":"JOSEPH","nickname":null,"middle_name":null,"last_name":"MCGOWAN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":77887,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"PIRON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145109,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":null,"last_name":"DURR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":73302,"prefix":null,"prefix_display":null,"first_name":"COURTNEY","nickname":null,"middle_name":null,"last_name":"LEE-ASHLEY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151835,"prefix":null,"prefix_display":null,"first_name":"PETER","nickname":null,"middle_name":null,"last_name":"STEHOUWER","suffix":null,"suffix_display":null},"covered_position":null,"new":true},{"lobbyist":{"id":68805,"prefix":null,"prefix_display":null,"first_name":"TAYLOR","nickname":null,"middle_name":null,"last_name":"BOOTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]},{"url":"https://lda.gov/api/v1/filings/956076c6-86a3-42ed-bf18-8375d3295b7b/","filing_uuid":"956076c6-86a3-42ed-bf18-8375d3295b7b","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/956076c6-86a3-42ed-bf18-8375d3295b7b/print/","filing_document_content_type":"text/html","income":null,"expenses":"7360000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Paul J. Larsen","dt_posted":"2026-07-20T15:46:20-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"670 Maine Avenue, SW","registrant_address_2":"Suite 1000","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20024","registrant":{"id":31350,"url":"https://lda.gov/api/v1/registrants/31350/","house_registrant_id":30654,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","description":null,"address_1":"670 Maine Avenue, SW","address_2":"Suite 1000","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20024","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"PAUL J. LARSEN","contact_telephone":"+1 202-835-3400","dt_updated":"2026-07-30T11:08:37.463508-04:00"},"client":{"id":138226,"url":"https://lda.gov/api/v1/clients/138226/","client_id":12,"name":"PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2007-08-14"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 4: Rescissions Act of 2025 (Public Law 119-28) H.R. 4121: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 8646: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 S.___: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2027 H. Res. 566: Providing for consideration of the Senate amendment to the bill (H.R. 1) to provide for reconciliation pursuant to title II of H. Con. Res. 14 H.R. 9310: Department of Homeland Security Appropriations Act, 2027 S. 2256: Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2026 H.R. 5304: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 S. 2587: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026 H.R. 9260: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 S.___: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027 H.R. 5342: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 6938: Commerce, Justice, Science; Energy and Water Development; and Interior and Environment Appropriations Act, 2026 (Public Law 119-74) H.R. 8845: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S.___: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2027 S. 2354: Commerce, Justice, Science, and Related Agencies Appropriations Act, 2026 H.R. 5371: Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (Public Law 119-37) S. 1071: National Defense Authorization Act for Fiscal Year 2026 (Public Law 119-60) S. 2296: National Defense Authorization Act for Fiscal Year 2026 H.R. 8800: National Defense Authorization Act for Fiscal Year 2027 S. 4784: National Defense Authorization Act for Fiscal Year 2027 S. 2: Secure America Act (Public Law 119-18) H.R. 7148: Consolidated Appropriations Act, 2026 (Public Law 119-75) Presidents Budget Fiscal Year 2027 Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Government funding policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41615,"prefix":null,"prefix_display":null,"first_name":"RANDY","nickname":null,"middle_name":null,"last_name":"BURKHOLDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"S. 43: Skinny Labels, Big Savings Act S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act S. 3452: Biological Intellectual Protection Act of 2025 H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act H.R. 6624: Biological Intellectual Property Protection Act of 2025 Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154901,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"JUDE","last_name":"DILORETO","suffix":null,"suffix_display":null},"covered_position":"None","new":true}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 355: FDA Modernization Act 3.0 S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864: HELP Copays Act S. 1387: National Biotechnology Initiative Act of 2025 S. 1414: Expedited Access to Biosimilars Act S. 1954: Biosimilar Red Tape Elimination Act S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) S. 2658: Medication Affordability and Patent Integrity Act S. 3014: Ensuring Timely Access to Generics Act of 2025 S. 3345: PBM Price Transparency and Accountability Act S. 3788: CLEAR LABELS Act H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) H.R. 946: ORPHAN Cures Act H.R. 1262: Mikaela Naylon Give Kids a Chance Act H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program H.R. 2214: DRUG Act H.R. 3521: Clinical Trial Modernization Act H.R. 4317: PBM Reform Act of 2025 H.R. 5256: 340B ACCESS Act H.R. 6423: HELP Copays Act H.R. 6610: Pharmacists Fight Back [in Federal Employee Health Benefit Plans Act] H.R. 7837: Most Favored Patients Act H.R. 7953: FAIR ACT H.R. 8269: CLEAR LABELS Act H.R. 9661: Expedited Access to Biosimilars Act Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues IRA price negotiation expansion policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Most Favored Nation (MFN) policy issues Drug importation policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Antimicrobial resistance policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues 340B rebate pilot program Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order: Lowering Drug Prices by Once Again Putting Americans First","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41615,"prefix":null,"prefix_display":null,"first_name":"RANDY","nickname":null,"middle_name":null,"last_name":"BURKHOLDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":149775,"prefix":null,"prefix_display":null,"first_name":"JAKE","nickname":null,"middle_name":null,"last_name":"FREED","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147771,"prefix":null,"prefix_display":null,"first_name":"NIELAH","nickname":null,"middle_name":null,"last_name":"TUCKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":62437,"prefix":null,"prefix_display":null,"first_name":"SYLVIA","nickname":null,"middle_name":null,"last_name":"YU","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154901,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"JUDE","last_name":"DILORETO","suffix":null,"suffix_display":null},"covered_position":"None","new":true},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"H.R. 1: One Big Beautiful Bill Act (Public Law 119-21) Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues Part D redesign and policy issues including non-interference and rebates policy issues Part B policy issues Drug cost and pricing policy issues Medicare rebate policy issues Center for Medicare and Medicaid Innovation (CMMI) policy issues CMS IPAY Guidance on the Medicare Drug Price Negotiation Program IPAY and Maximum Fair Prices policy issues Medicaid rebate policy issues GENErating cost Reductions for U.S. Medicaid (GENEROUS) model Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41615,"prefix":null,"prefix_display":null,"first_name":"RANDY","nickname":null,"middle_name":null,"last_name":"BURKHOLDER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":142246,"prefix":null,"prefix_display":null,"first_name":"JUDITH","nickname":null,"middle_name":null,"last_name":"HARON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146239,"prefix":null,"prefix_display":null,"first_name":"LAUREN","nickname":null,"middle_name":null,"last_name":"JEE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147771,"prefix":null,"prefix_display":null,"first_name":"NIELAH","nickname":null,"middle_name":null,"last_name":"TUCKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Proclamation: Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients Into the United States (April 2, 2026) S. 2296: BIOSECURE Act (S.Amdt. 3236 to National Defense Authorization Act for FY 2026) H.R. 4780: USTRx Act H.R. 6089: Biomanufacturing Excellence Act of 2025 H.R. 9102: Biotech Investment National Security Act of 2026 (BINSA) H.R. 9142: Prohibiting Adversarial Patents Act of 2026 (PAPA) Executive Order: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Tariff policy issues Most Favored Nation (MFN) policy issues Biopharmaceutical innovation policy issues International intellectual property and market access policy issues Pricing and reimbursement policy issues Supply chain policy issues WTO TRIPS waiver policy issues COINS Act implementation policy issues China outbound investment policy issues including COINS Act US-UK Framework Agreement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":152549,"prefix":null,"prefix_display":null,"first_name":"MEREDITH","nickname":null,"middle_name":null,"last_name":"ALLISON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":68966,"prefix":null,"prefix_display":null,"first_name":"TERESA","nickname":null,"middle_name":null,"last_name":"BILL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":145357,"prefix":"ms","prefix_display":"MS.","first_name":"ELENORA","nickname":"NORA","middle_name":null,"last_name":"CONNORS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146964,"prefix":null,"prefix_display":null,"first_name":"CATHERINE","nickname":null,"middle_name":"JANE","last_name":"DOUGLAS","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":67006,"prefix":null,"prefix_display":null,"first_name":"BART","nickname":null,"middle_name":null,"last_name":"FORSYTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152548,"prefix":null,"prefix_display":null,"first_name":"SAMANTHA","nickname":null,"middle_name":null,"last_name":"HELTON ABBOUD","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":29387,"prefix":null,"prefix_display":null,"first_name":"DAVID","nickname":null,"middle_name":null,"last_name":"KORN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":146241,"prefix":null,"prefix_display":null,"first_name":"FABIAN","nickname":null,"middle_name":null,"last_name":"LUCERO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":112885,"prefix":null,"prefix_display":null,"first_name":"JOHN","nickname":null,"middle_name":null,"last_name":"NAPPI","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139422,"prefix":"mr","prefix_display":"MR.","first_name":"TOM","nickname":null,"middle_name":null,"last_name":"O'BRIEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":150986,"prefix":"ms","prefix_display":"MS.","first_name":"MARIA","nickname":null,"middle_name":"PATTERSON","last_name":"OLSON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":18361,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"REILLY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140503,"prefix":null,"prefix_display":null,"first_name":"ZACH","nickname":null,"middle_name":null,"last_name":"SENTEMENTES","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":140502,"prefix":null,"prefix_display":null,"first_name":"ANNIE","nickname":null,"middle_name":null,"last_name":"WOERPEL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":41619,"prefix":"mr","prefix_display":"MR.","first_name":"MICHAEL","nickname":null,"middle_name":"PAUL","last_name":"WOODY","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":66321,"prefix":null,"prefix_display":null,"first_name":"KELLY","nickname":null,"middle_name":null,"last_name":"GOLDBERG","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":139656,"prefix":null,"prefix_display":null,"first_name":"JOCELYN","nickname":null,"middle_name":null,"last_name":"ULRICH","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":154901,"prefix":"mr","prefix_display":"MR.","first_name":"MATTHEW","nickname":null,"middle_name":"JUDE","last_name":"DILORETO","suffix":null,"suffix_display":null},"covered_position":"None","new":true}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":11,"name":"Executive Office of the President (EOP)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":41,"name":"Treasury, Dept of"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}]}